Iron Deficiency Anemia Therapy Market By Therapy Type (Oral Iron Supplements, Intravenous Iron Therapy, Erythropoiesis-Stimulating Agents); By Route of Administration (Oral, Intravenous); By End User (Hospitals, Clinics, Homecare, Specialty Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Iron Deficiency Anemia Therapy Market: Infusion Convenience, Payer Preference and Prescription Oral Innovation Reshape Commercial Value

The Global Iron Deficiency Anemia Therapy Market is estimated to reach USD 5.19 billion in 2025 and is projected to grow to USD 8.95 billion by 2032, expanding at a CAGR of 8.1% during the forecast period, according to Strategic Market Research.

 

The iron deficiency anemia therapy market is a drug-driven healthcare market in which treatment value is divided between high-volume oral iron and higher-value intravenous formulations. Generic ferrous salts remain the initial therapy for most suitable patients because of their low cost and broad availability. Intravenous iron is generally used when oral treatment is not tolerated, fails to restore iron stores or is unlikely to be absorbed adequately. The commercially important transition is therefore not between medical and surgical care, but between inexpensive pharmacy-based treatment and reimbursed infusion-based therapy. (PubMed)

 

The market extends across primary care, obstetrics and gynecology, gastroenterology, hematology, nephrology, dialysis centers, hospitals and outpatient infusion facilities. Treatment demand may be temporary when a reversible deficiency is corrected, but recurrent blood loss, malabsorption, chronic kidney disease, inflammatory disorders and repeated pregnancy-related requirements create repeat prescription and retreatment opportunities. Product selection depends on more than clinical eligibility: oral tolerability, infusion frequency, medical-benefit coverage, pharmacy formularies, prior authorization, hospital procurement and dialysis budgeting determine which patients progress to premium products.

 

Anemia Burden Creates a Large Diagnostic Funnel, but IDA Conversion Is Selective

The Global Burden of Disease 2021 assessment estimated that anemia affected 1.92 billion people worldwide, equivalent to approximately 24.3% of the global population. Iron deficiency was the leading cause-specific contributor to anemia-related disability. Anemia also results from inflammation, infection, inherited blood disorders, kidney disease and other nutritional deficiencies, while iron deficiency can exist without anemia. (HealthData)

Women and children account for a substantial share of the screening and supplementation opportunity. WHO’s 2025 edition of the global anemia estimates reported that 30.7% of women aged 15–49 had anemia in 2023, including 35.5% of pregnant women and 30.5% of non-pregnant women. Persistent burden among menstruating, pregnant and postpartum populations supports demand through obstetric practices, women’s-health clinics, primary care, public maternal-health programs and hospital infusion departments. (World Health Organization)

U.S. data indicate that the iron-treatment funnel is considerably larger than the diagnosed IDA population. A nationally representative analysis of 8,021 adults using 2017–2020 NHANES data estimated absolute iron deficiency in 14% of adults and functional iron deficiency in 15%. Absolute deficiency reached 34% among women aged 18–49, compared with 3% among men in the same age range. Only a minority of iron-deficient respondents reported using iron supplements, indicating substantial leakage between deficiency, diagnosis and active treatment. (JAMA Network)

Adolescent and young-adult women represent another underdiagnosed treatment segment. Analysis of U.S. females aged 12–21 between 2003 and 2020 estimated iron deficiency in 38.6% and iron deficiency anemia in 6.3%, although results varied according to ferritin and hemoglobin thresholds. This diagnostic sensitivity affects commercial forecasting: broader ferritin cutoffs enlarge the screening population but do not automatically create prescription or infusion demand. (PMC)

Market conversion therefore depends on active testing, confirmation of iron deficiency, identification of the underlying cause, treatment initiation and persistence. Women’s health, adolescent medicine and chronic-disease programs provide the strongest opportunities to improve conversion because these channels can combine risk recognition, laboratory testing and follow-up within an established care pathway.

 

Oral Iron Retains Volume Leadership While Tolerability Limits Persistence

Generic oral ferrous sulfate, ferrous fumarate and ferrous gluconate form the price-sensitive base of the market. The American Gastroenterological Association identifies ferrous sulfate as the least-expensive oral formulation and does not establish a clear efficacy advantage for one oral product over another. Once-daily or alternate-day administration may improve tolerability for some patients, but gastrointestinal effects and incomplete adherence continue to create treatment failure and discontinuation. (PubMed)

Retail availability gives oral iron the broadest access across primary care, pharmacies, maternity programs and self-pay channels. The same accessibility weakens market visibility. OTC purchases, private-label products, multivitamins, public supplementation and low-cost generic prescriptions are not captured in a single national database, limiting reliable estimates of product share and treated-patient volume.

Manufacturers in this segment compete through formulation, tolerability, dosing convenience, pediatric formats, taste, packaging and distribution rather than strong molecule-level differentiation. Government tenders and public-health programs add large unit volumes but impose substantial price and supply-chain pressure. Suppliers with low manufacturing costs and reliable distribution are better positioned than premium brands in mass supplementation channels.

Oral treatment also functions as a payer-mandated gateway to IV therapy. When insurers require documented failure, intolerance or contraindication to oral iron, generic tablets become part of the utilization-management process for branded infusions. Oral therapy therefore controls both the market’s largest probable patient-volume segment and the rate at which patients move into its highest-value segment.

 

IV Iron Concentrates Revenue Around Reimbursed Treatment Events

Intravenous iron generates a smaller patient base than oral therapy but captures substantially more value per treatment course. Hospitals, physician offices, outpatient infusion centers and dialysis providers purchase and administer IV products under medical-benefit reimbursement or bundled institutional budgets. Manufacturers must therefore secure formulary placement, payer authorization, distributor access and infusion-site adoption rather than relying only on prescriber awareness.

Direct Medicare data illustrate the scale of realized premium demand. In 2024, ferric carboxymaltose accounted for 73,227 Medicare Part B beneficiaries, 147,599 claims and USD 131.27 million in spending. Ferric derisomaltose accounted for 41,976 beneficiaries, 54,677 claims and USD 107.99 million. These figures cover Medicare Part B rather than the complete U.S. market, but they demonstrate that two premium IV products alone generated more than USD 239 million in transparent reimbursed spending during the year.

Administration frequency has become an important competitive variable. Guidance recommends IV formulations capable of replacing the iron deficit in one or two infusions when clinically appropriate. Fewer visits can reduce chair occupancy, staff time, patient travel, missed work and scheduling pressure, giving high-dose products an operational advantage over formulations requiring several administrations. (PubMed)

Ferric derisomaltose is positioned around this limited-administration model. The U.S. label allows a 1,000 mg infusion as a single dose for adults weighing at least 50 kg, with repeat treatment permitted when IDA recurs. The value proposition combines rapid iron replacement with fewer facility visits, although payers may still prefer lower-cost multi-dose products when acquisition savings outweigh administration costs. (DailyMed)

Premium IV revenue is therefore determined by total-course economics rather than drug price alone. Infusion centers evaluate acquisition cost, reimbursement spread, chair utilization and staffing. Payers compare preferred-product contracts and step-therapy savings. Patients and clinicians weigh the number of visits against treatment urgency and oral-treatment history. Products that reduce administration burden can defend value, but only when manufacturers translate convenience into accepted payer and provider economics.

 

Prescription Oral Products Build a Commercial Bridge Before Infusion

Differentiated prescription oral products are developing an intermediate market between commodity ferrous salts and IV treatment. These therapies target patients who need prescription-level management but may wish to avoid infusion, as well as those who experience difficulties with conventional salts. Their commercial performance depends on pharmacy-benefit coverage, net price, prescriber familiarity and evidence that the formulation can retain patients within the oral pathway.

Shield Therapeutics reported approximately 199,000 Accrufer prescriptions in 2025, up 33% from about 150,000 in 2024. The company reported total revenue of approximately USD 50 million and an average net price of USD 223 during 2025. The prescription trajectory provides direct evidence of demand for a differentiated oral product, although its volume remains small compared with the probable use of OTC and generic iron. (Shield Therapeutics)

The FDA expanded Accrufer’s indication in December 2025 to include pediatric patients aged 10 years and older with iron deficiency. The product had previously been approved for adults. Pediatric approval enlarges the addressable prescription population and provides access to adolescent-medicine and pediatric gastroenterology channels, where conventional oral tolerability and adherence can be commercially important barriers. (U.S. Food and Drug Administration)

Label expansion does not ensure immediate commercial adoption. Insurers may favor inexpensive generic iron, prescribers may continue established treatment routines and families may face higher cost sharing for branded oral therapy. Shield and future prescription-oral competitors must demonstrate that improved treatment persistence or avoided infusion costs justify formulary access.

Prescription oral therapy nevertheless offers a strategically attractive position. It can capture patients who have not responded well to conventional salts but do not yet satisfy IV authorization requirements. Growth in this segment could reduce some infusion conversion while expanding the monetized oral market beyond low-price generics.

 

CKD and Dialysis Provide Recurring Demand Under Tight Cost Control

Chronic kidney disease and dialysis represent important recurring-use settings for iron therapy. Patients may require repeated iron assessment and replacement, while nephrologists, dialysis protocols and facility formularies influence product selection. Clinical recurrence supports treatment volume, but consolidated procurement and bundled reimbursement make the segment highly price sensitive.

CMS expected Medicare to pay USD 6.6 billion to approximately 7,700 ESRD facilities in 2025, based on an ESRD Prospective Payment System base rate of USD 273.82 per dialysis treatment. The bundle includes drugs and biological products used in outpatient maintenance dialysis, giving facilities a direct incentive to manage total cost per treatment. (Centers for Medicare & Medicaid Services)

This payment structure favors suppliers that can provide predictable pricing, large-volume contracts and reliable availability. Premium convenience has less value when the patient already attends a dialysis facility several times per week, while acquisition cost and protocol standardization carry more weight. Iron sucrose and other established formulations can therefore retain strong institutional demand despite competition from newer high-dose products.

Non-dialysis CKD offers a different commercial balance. Patients who do not visit a dialysis center regularly may place greater value on completing iron replacement in fewer infusions. Manufacturers can segment nephrology accounts according to dialysis status, infusion access and reimbursement rather than treating CKD as a single purchasing market.

 

Payer Step Therapy Restricts the Premium Addressable Population

Regulatory approval defines who can receive a product, but payer policy determines how many eligible patients can access it commercially. UnitedHealthcare’s IV iron policy effective February 1, 2026 requires documentation supporting the IDA diagnosis and commonly requires oral-treatment failure, intolerance or contraindication. In some CKD pathways, patients must also fail or be unable to tolerate preferred IV therapies before receiving selected nonpreferred brands. (UHC Provider)

UnitedHealthcare’s 2026 Medicare Part B step-therapy policy lists Injectafer and Monoferric as nonpreferred products while identifying Feraheme, Ferrlecit, INFeD and Venofer as preferred options. Existing patients may receive continuity protection, but new-patient share is more directly exposed to payer preference. (UHC Provider)

These policies shift commercial investment toward reimbursement teams, prior-authorization support, account contracting and health-economic evidence. Sales representatives cannot create sustained volume where infusion sites face claim denials or unfavorable acquisition economics. Manufacturers must demonstrate either superior clinical suitability for a defined patient or a total-course cost advantage that includes administration burden.

Reauthorization requirements also create recurring documentation work. Updated laboratory values and evidence of continued medical necessity can delay repeat courses, reducing realized demand even among patients with recurrent deficiency. Payer access is therefore one of the largest differences between epidemiological need and branded IV revenue.

 

Public Programs Create Scale Without Premium Pricing

India illustrates the difference between healthcare volume and pharmaceutical value. Under the Anemia Mukt Bharat program, 47 million children aged 6–59 months received repeated iron-folic-acid syrup doses in the second quarter of FY2024–25, while 49 million children aged 5–9 received IFA tablets and 59 million aged 10–19 received adolescent formulations. The program also supplied IFA tablets to approximately 15 million pregnant women and 9 million lactating women.

These volumes support demand for standardized oral formulations, contract manufacturing, packaging and nationwide distribution. Public procurement, however, is primarily preventive or supplementary and should not be treated as branded IDA therapy revenue. Tender price, quality compliance, manufacturing reliability and last-mile delivery determine supplier competitiveness.

Similar programs across lower- and middle-income countries broaden the market for inexpensive iron salts and combination products. Premium IV therapy remains concentrated in hospital and specialist settings, while mass public-health demand rewards suppliers capable of producing large quantities at low unit cost.

 

Competitive Performance Reflects Both Volume Growth and Price Erosion

CSL Vifor reported USD 1.034 billion in iron-therapy revenue for FY2025, an increase of 1%. Global volume growth and higher Ferinject sales in China supported performance, while generic competition in Europe constrained revenue. Ferinject/Injectafer generated USD 766 million, Venofer USD 172 million and Maltofer USD 91 million within the reported portfolio.

The results confirm the commercial scale of IV iron but also indicate that mature markets are moving from protected brand growth toward contracting, geographic expansion and lifecycle defense. European generic pressure can reduce price and tender share even when treatment volume remains stable or increases. China and other reimbursement-expansion markets provide a counterweight where access gains can increase treated-patient penetration.

American Regent’s results point to competitive pressure in the U.S. injectable market. Daiichi Sankyo reported that American Regent unit revenue declined 15.1% in local currency to USD 1.208 billion in the year ended March 2026, partly because of lower Injectafer and Venofer sales. The unit contains products beyond iron therapy, so the result cannot be interpreted as a direct market-share measure, but it identifies weakening performance for two major iron brands within the portfolio.

Pharmacosmos competes through Monoferric’s single-dose administration, while Shield Therapeutics is building a prescription oral franchise. CSL Vifor combines a broad iron portfolio and international market access, and American Regent maintains established infusion and dialysis relationships. Competitive positioning increasingly reflects channel role: low-cost suppliers compete for tenders and preferred status, high-dose IV brands compete on total-course convenience, and prescription oral companies compete to keep patients out of the infusion pathway.

 

Market Outlook: Value Will Follow Access, Convenience and Treatment Persistence

Iron deficiency anemia therapy demand will remain broad, but growth will not be uniform across segments. Generic oral iron will continue to account for the largest probable treatment volume while generating limited pricing power. Public supplementation programs will add substantial units without creating equivalent revenue. Branded IV formulations will retain the highest value per treatment course but face step therapy, institutional procurement and generic erosion.

Limited-administration IV products are positioned to gain where infusion capacity, patient travel and staff time create measurable costs. Dialysis organizations will continue to prioritize acquisition economics because treatment is delivered inside a bundled, recurring care model. Prescription oral products can expand the monetized pharmacy segment when manufacturers secure formulary coverage and demonstrate better persistence than conventional salts.

Women of reproductive age, adolescents, patients with recurrent gastrointestinal blood loss, people with impaired absorption and patients with CKD provide the most commercially relevant treatment funnels. Suppliers that connect screening and diagnosis to durable treatment—rather than relying on anemia prevalence alone—will generate the most defensible demand.

 

Iron Deficiency Anemia Therapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.19 Billion
Revenue Forecast in 2032	USD 8.95 Billion
Overall Growth Rate	CAGR of 8.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Therapy Type	Oral Iron Supplements; Intravenous Iron Therapy; Erythropoiesis-Stimulating Agents
By Route of Administration	Oral; Intravenous
By End User	Hospitals; Clinics; Homecare; Specialty Centers
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Rising Iron Deficiency Burden	Increasing prevalence of iron deficiency among women, children, chronic disease patients, and high-risk populations is expanding the treatment funnel for anemia management.
Market Drivers – Growth of Intravenous Iron Adoption	Increasing preference for high-dose IV iron therapies in patients with oral intolerance, poor absorption, recurrent deficiency, and chronic conditions is supporting premium treatment demand.
Market Drivers – Innovation in Oral and Prescription Therapies	Development of differentiated oral iron formulations with improved tolerability, adherence, and prescription positioning is creating opportunities beyond low-cost generic supplements.
Customization Option	Available upon request